July 15, 2025
Ms. Brown (for herself, Ms. Clarke of New York, Ms. Sewell, Mrs. Foushee, Ms. McClellan, Ms. Velázquez, Mr. Fields, Ms. Kelly of Illinois, Mrs. Dingell, Ms. Tlaib, Mrs. Trahan, Mr. Johnson of Georgia, Ms. Ansari, Mrs. Watson Coleman, Mr. David Scott of Georgia, Mr. Thanedar, Mr. Thompson of Mississippi, Mr. Krishnamoorthi, Ms. Salinas, Mrs. McIver, Mr. Carter of Louisiana, Ms. Meng, Ms. Wilson of Florida, Ms. Lee of Pennsylvania, Ms. Simon, Ms. Wasserman Schultz, Mr. Figures, Ms. Adams, Mr. Khanna, Ms. Underwood, Mr. Green of Texas, Ms. Tokuda, Ms. Rivas, Mr. Mannion, Ms. Pressley, Ms. Titus, and Mr. Latimer) introduced the following bill; which was referred to the Committee on Energy and Commerce
To authorize the Secretary of Health and Human Services to award grants to increase early detection of and intervention for uterine fibroids, and for other purposes.
Section 1. Short title
This Act may be cited as the Uterine Fibroid Intervention and Gynecological Health Treatment Act of 2025
.
Sec. 2. Research on uterine fibroid early detection and intervention
(a) In general
The Secretary of Health and Human Services (in this Act referred to as the Secretary
) shall—
(1)
conduct or support research on increasing early detection of, and intervention for, uterine fibroids; and
(2)
based on the results of such research and other relevant information, formulate evidence-based or evidence-informed strategies to increase early detection in health care settings.
(b) Timeline
The Secretary shall finalize the evidence-based or evidence-informed strategies required by subsection (a)(2) as expeditiously as possible in order to make such strategies available to grantees under section 3 to implement such strategies pursuant to section 3(b)(3).
Sec. 3. Grants with respect to uterine fibroid early detection and intervention
(a) In general
The Secretary of Health and Human Services (in this Act referred to as the Secretary
) may award grants to States for carrying out programs—
(1)
to increase early detection of and intervention for uterine fibroids; and
(2)
to develop and implement public awareness and education campaigns for the early detection and intervention of uterine fibroids.
(b) Use of funds
A State receiving a grant under this section may use the grant, with respect to increasing early detection of and intervention for uterine fibroids, for the following activities:
(1)
Screening procedures, including advanced gynecological imaging (including payment therefor).
(2)
Patient navigation services.
(3)
Implementation of evidence-based or evidence-informed strategies proven to increase early detection in health care settings.
(4)
Facilitating access to health care settings.
(c) Priority
In awarding grants under this section, the Secretary shall give priority to States proposing to carry out a program in a geographic areas in which there are socially vulnerable populations with elevated risk of uterine fibroid development.
Sec. 4. Research with respect to uterine fibroid early detection and intervention
The Secretary may award grants to conduct research, which may include clinical trials, related to—
(1)
disparities in pain control and management in uterine fibroid surgical treatment; or
(2)
Asherman’s Syndrome, intrauterine adhesions, and other intrauterine conditions as determined appropriate by the Secretary.
Sec. 5. Reports to Congress
(a) Reports on grants
Not later 2 years after the initial award of grants under this Act, and every 2 years thereafter, the Secretary shall submit to the Congress, and make publicly available on the appropriate website of the Department of Health and Human Services, a report summarizing the findings and results of programs and activities funded through grants under this Act.
(b) Report on research developments
Not later than 2 years after the date of enactment of this Act, and every 2 years thereafter, the Secretary shall submit to the Congress, and make publicly available on the appropriate website of the Department of Health and Human Services, a report outlining research developments and findings related to—
(2)
disparities in pain control and management in uterine fibroid surgical treatment; and
(3)
Asherman’s Syndrome, intrauterine adhesions, and other intrauterine conditions as determined appropriate by the Secretary.